Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNK Cells Maintenance in SCLC
NCT06747832Phase 1Enrolling by invitation
- Sponsor
- Guangzhou Ruixin Biotechnological
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iPSC-derived natural killer cells in small cell lung cancer (SCLC), sponsored by Guangzhou Ruixin Biotechnological. Primary endpoints: Number of Participants with Adverse Event at 12 months and Objective Response Rate at 12 months. Started Dec 2024; status: enrolling by invitation.
02
Drugs
iPSC-derived natural killer cells
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06747832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747832.